CStone Pharmaceuticals (HKG:2616)
5.04
-0.05 (-0.88%)
Oct 21, 2026, 4:08 PM HKT
CStone Pharmaceuticals Employees
CStone Pharmaceuticals had 147 employees as of June 30, 2026. The number of employees increased by 11 or 8.09% since the number was reported on December 31, 2025. That makes CStone Pharmaceuticals the 28,989th largest employer in the world and 1,848th in Hong Kong.
Employees
147
Change
11
Growth
8.09%
Revenue / Employee
3.34M HKD
Profits / Employee
-3.29M HKD
Market Cap
8.02B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 147 | 11 | 8.09% |
| Dec 31, 2025 | 136 | 1 | 0.74% |
| Dec 31, 2024 | 135 | -95 | -41.30% |
| Dec 31, 2023 | 230 | -246 | -51.68% |
| Dec 31, 2022 | 476 | -135 | -22.09% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Shanghai Haohai Biological Technology | 1,999 |
| Ascentage Pharma Group International | 828 |
| Lepu Biopharma | 646 |
| Alphamab Oncology | 515 |
| Suzhou Ribo Life Science | 453 |
| CARsgen Therapeutics Holdings | 424 |
| HBM Holdings | 327 |
| Ascletis Pharma | 217 |
CStone Pharmaceuticals News
- 7 weeks ago - CStone Pharmaceuticals Earnings release: H1 2026 - Filings
- 7 weeks ago - CStone Pharmaceuticals Slides: H1 2026 - Filings
- 7 weeks ago - CStone Pharmaceuticals Quarterly report: H1 2026 - Filings
- 3 months ago - CStone Pharmaceuticals Enters into Exclusive Commercialization Agreement with Arrotex for Sugemalimab across Australia and New Zealand - PRNewsWire
- 4 months ago - ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept - PRNewsWire
- 6 months ago - CStone Presented Preclinical Data for Three Novel or Differentiated ADCs at AACR 2026, Including CS5007 (EGFR/HER3) - PRNewsWire
- 6 months ago - CStone Announces 2025 Annual Results: Accelerated Expansion of Global Commercial Footprint and Efficient Advancement of Innovation Pipeline 2.0 - PRNewsWire
- 6 months ago - CStone Updated Clinical Progress and Key Phase I/II Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) - PRNewsWire